Singapore markets closed
Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,484.38 +6.48 (+0.12%) Dow
39,226.32 +98.52 (+0.25%) Nasdaq
17,840.07 +34.92 (+0.20%) Bitcoin USD
61,985.75 +331.55 (+0.54%) CMC Crypto 200
1,294.91 +28.77 (+2.27%)
PCVX Sep 2024 40.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 1.4500 |
| Open | 1.1500 |
| Bid | 0.1000 |
| Ask | 5.0000 |
| Strike | 40.00 |
| Expiry date | 2024-09-20 |
| Day's range | 1.1500 - 1.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.